Abstract
The 12th ICACT meeting was excellent in reviewing state-of-the-art management approaches to patients with cancer, and was also outstanding in presenting the rationale and background for many worldwide studies incorporating novel therapeutic approaches. The meeting also set the platform for understanding the mechanisms behind new therapeutic targets being used alone, or most likely in combination with existing therapies, and discussed the implications of their use in ongoing phase I, II, and trials.
Original language | English (US) |
---|---|
Pages (from-to) | 222-223 |
Number of pages | 2 |
Journal | IDrugs |
Volume | 5 |
Issue number | 3 |
State | Published - 2002 |
ASJC Scopus subject areas
- Pharmacology
- Drug Discovery